칠레 - 스페인어 - ISPC (Instituto de Salud Pública de Chile)

novo nordisk farmacÉutica ltda. - somapacitan - sin formulas

칠레 - 스페인어 - ISPC (Instituto de Salud Pública de Chile)

novo nordisk farmacÉutica ltda. - (somapacitán) - sin formulas

미국 - 영어 - NLM (National Library of Medicine)

novo nordisk - somapacitan (unii: 8foj430u94) (somapacitan - unii:8foj430u94) -  sogroya is indicated for the: sogroya is contraindicated in patients with:   risk summary there are no available data on the use of sogroya during pregnancy; however, published studies describing the use of short-acting recombinant growth hormone (rhgh) during pregnancy over several decades have not identified any drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, subcutaneously administered somapacitan-beco was not teratogenic in rats or rabbits during organogenesis at doses approximately 12 times the clinical exposure at the maximum recommended human dose (mrhd) of 8 mg/week. no adverse developmental outcomes were observed in a pre- and post-natal development study with administration of somapacitan-beco to pregnant rats from organogenesis through lactation at approximately 275 times the clinical exposure at the mrhd (see data) . the background risk of birth defects and miscarriage for the indicated population is unknown. in the

폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

galex d.d. - peryndopryl z tert-butyloaminą; indapamidum - tabletki - 2 mg + 0,625 mg

폴란드 - 폴란드어 - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

galex d.d. - indapamidum; peryndopryl z tert-butyloaminą - tabletki - 4 mg + 1,25 mg

유럽 연합 - 불가리아어 - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - Растеж - Хипофизни и хипоталамични хормони и аналози - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

유럽 연합 - 라트비아어 - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - izaugsme - hipofīzes un hipotalāma hormoni un analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

유럽 연합 - 몰타어 - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - tkabbir - ormoni u analogi pitwitarji u ipotalamiċi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

유럽 연합 - 리투아니아어 - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - augimas - hipofizės ir hipotalaminiai hormonai ir analogai - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

유럽 연합 - 크로아티아어 - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - rast - hipofiza i hipotalamusni hormoni i analozi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).